Investing

Phathom Pharmaceuticals : PHAT

PHAT

Stock Data

$8.87

$0.27 (3.14%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Phathom Pharmaceuticals Inc is a biopharmaceutical company based in Florham Park, New Jersey, dedicated to creating treatments for gastrointestinal diseases. It specializes in a novel acid blocker, vonoprazan, aimed at managing conditions like erosive gastroesophageal reflux disease and Helicobacter pylori infections. With rights in the U.S., Europe, and Canada, Phathom is at the forefront of addressing unmet medical needs in digestive health since its founding in 2018.

Latest Activity

PHATPhathom Pharmaceuticals

Q2 2026

Jul 30, 7:05am ET

EPS

$0.00

est -$0.10+$0.10

Revenue

$74M

est $73M+2.2%

Phathom swung to non-GAAP operating profitability as VOQUEZNA prescriptions nearly doubled year-over-year to 325,000, crushing EPS expectations despite trimming full-year revenue guidance to $310M-$325M from $320M-$345M.

ShareRead more

All Phathom Pharmaceuticals Articles

1 Article

Joel South | Mar 27, 2026 at 11:07 AM EDT

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to…